Here, we show that glioma driver mutation VAF, which is included in most NGS reports, can serve as a useful metric for judging the reliability of MGMT promoter methylation pyrosequencing results, more so than microscopic cellularity estimates. The gene discussed is MGMT; the disease is central nervous system cancer.